Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Cash from Operations (2016 - 2025)

Moleculin Biotech's Cash from Operations history spans 10 years, with the latest figure at 5366000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 5366000.0 for Q4 2025, down 5.57% from a year ago — trailing twelve months through Dec 2025 was 22735000.0 (up 4.72% YoY), and the annual figure for FY2025 was 22735000.0, up 4.72%.
  • Cash from Operations for Q4 2025 was 5366000.0 at Moleculin Biotech, up from 7223000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3624000.0 in Q1 2021 to a low of 8006000.0 in Q2 2022.
  • The 5-year median for Cash from Operations is 5765500.0 (2024), against an average of 5838900.0.
  • The sharpest move saw Cash from Operations plummeted 76.21% in 2022, then surged 35.97% in 2023.
  • Year by year, Cash from Operations stood at 4251000.0 in 2021, then crashed by 70.69% to 7256000.0 in 2022, then skyrocketed by 32.51% to 4897000.0 in 2023, then decreased by 3.8% to 5083000.0 in 2024, then dropped by 5.57% to 5366000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 5366000.0, 7223000.0, and 5582000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.